Pfizer will be able to deliver 200 million COVID-19 vaccine doses by the end of May

Pfizer-BioNTech COVID-19 vaccine.
(Image credit: INA FASSBENDER/AFP via Getty Images)

Pfizer will be able to provide the United States with 200 million doses of the COVID-19 vaccine it developed alongside BioNTech by the end of May, CEO Albert Bourla said Tuesday, per Bloomberg. That's two months ahead of the previous July 31 deadline the company had set for itself.

The reason for the apparent fast-tracking is actually a Food and Drug Administration-approved label change, which went into effect Monday, allowing health care workers to extract an additional sixth dose from each vial, so production levels won't necessarily increase. Bourla also said the alteration means Pfizer will be able to deliver 120 million doses to the U.S. by the end of March, 20 million more than promised when the vaccine was initially granted emergency use.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.